Project: GT-002 for the treatment of schizophrenia.
The aim is to advance a new drug candidate (GT-002) through Phase 1 clinical studies in healthy volunteers for later development of clinical proof of concept in the treatment of schizophrenia. Healthy male volunteers will first be administered GT-002 in a Single Ascending Dose (SAD) study, combined with assessment of food effects on absorption, followed by a Multiple Ascending Dose (MAD) study. Additional single-dose studies will confirm target engagement with PET imaging and EEG analysis.
Acronym | GASH02 (Reference Number: 10687) |
Duration | 01/03/2016 - 01/03/2019 |
Project Topic | Biological Sciences / Technologies |
Network | Eurostars 2 |
Call | Eurostars Cut-Off 5 |